Use of memantine for the treatment of dementia

References

• Querfurth HW, LaFerla FM. Mechanisms of disease: Alzheimer’s disease. N. Engl. J. Med.362, 329–344 (2010).
   PubMed Web of Science ®Google Scholar
• Hermann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin. Pharmacother.12(5), 787–800 (2011).
   PubMedGoogle Scholar
• Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clin. Interv. Aging4, 367–377 (2009).
   PubMed Web of Science ®Google Scholar
• Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol.6, 55–78 (2008).
   PubMed Web of Science ®Google Scholar
• Kavirajan H. Memantine: a comprehensive review of safety and efficacy. Expert Opin. Drug Saf.8(1), 89–109 (2009).
   PubMed Web of Science ®Google Scholar
• Jones RW, Bayer A, Inglis F, Barker A, Phul R. Safety and tolerability of once-daily versus twice-daily memantine: a randomized, double-blind study in moderate to severe Alzheimer’s disease. Int. J. Geriatr. Psychiatry22, 258–262 (2007).
   PubMed Web of Science ®Google Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-BEST Study (Benefit and Efficacy in Severely Demented Patients During Treatment with Memantine). Int. J. Geriatr. Psychiatry14, 135–146 (1999).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med.348, 1333–1341 (2003).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol.63, 49–54 (2006).
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Tariot PN, Meyers B, Resnick EM. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Discord.21, 136–143 (2007).
   PubMed Web of Science ®Google Scholar
• Livingston G, Katona C. The place of memantine in the treatment of Alzheimer’s disease: a number needed to treat analysis. Int. J. Geriatr. Psychiatry19, 919–925 (2004).
   PubMedGoogle Scholar
• Rasmusson DD, Banerjee PK, Semba K. Synergistic effects of acetylcholinesterase (AChE) inhibition and NMDA receptor modulation of acetylcholine levels. Biol. Psychiatry59(8 Suppl. 1), 2055–2056 (2006).
   Google Scholar
• Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil a randomized controlled trial. JAMA291, 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Choi SH, Park KW, Na DL et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multi-center, randomized, open-label, parallel study group. Curr. Med. Res. Opin.27(7), 1375–1383 (2011).
   PubMed Web of Science ®Google Scholar
• Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere J-J, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract.60(1), 110–118 (2006).
   PubMed Web of Science ®Google Scholar
• Atri A, Shaughness LW, Locascio JJ, Growden JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Discord.22, 209–221 (2008).
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry80(6), 600–607 (2009).
   PubMed Web of Science ®Google Scholar
• Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res. Ther.1(2), 7 (2009).
   PubMed Web of Science ®Google Scholar
• Maidment IA, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann. Pharmacother.42, 32–38 (2008).
   PubMedGoogle Scholar
• Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am. J Geriatr. Psychiatry12, 704–715 (2006).
   Google Scholar
• Pomara N, Ott BR, Peskind E, Resnick EM. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis. Assoc. Discor.21(1), 60–64 (2007).
   PubMed Web of Science ®Google Scholar
• Bakchine S, Loft H. Memantine Treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J. Alzheimers Dis.12, 97–107 (2008).
   Google Scholar
• McShane R, Sastre AA, Minkaran N. Memantine for dementia (review). Cochrane Database Syst Rev.1, 1469–493X (2009).
   Google Scholar
• Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized double-blind, placebo-controlled trial. Curr. Alzheimers Res.5, 83–89 (2008).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch. Neurol.68(8), 991–998 (2011).
   PubMed Web of Science ®Google Scholar
• Petersen RC. Mild cognitive impairment. N. Engl. J. Med.364, 2227–2234 (2011).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Insel PS, Weiner MW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s disease neuroimaging initiative. Arch. Neurol.68(1), 58–66 (2011).
   PubMedGoogle Scholar
• Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies a double-blind, placebo-controlled, multicentre trial. Lancet Neurol.8(7), 613–618 (2009).
   PubMed Web of Science ®Google Scholar
• Litvinenko IV, Odinak MM, Mogil’naya VI, Perstnev SV. Use of Memantine (akatinol) for the correction of cognitive impairments in Parkinson’s disease complicated by dementia. Neurosci. Behav. Physiology40(2), 149–155 (2010).
   PubMedGoogle Scholar
• Emre M, Tsolaki M, Bonuccelli U et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomized, double-blind, placebo-controlled trial. Lancet Neurol.9, 969–977 (2010).
   PubMed Web of Science ®Google Scholar
• Hu B, Ross L, Neuhaus J et al. Off-label medication use in frontotemporal dementia. Am. J Alzheimers. Dis. Other. Demen.5(2), 128–133 (2010).
   Google Scholar
• Diehl-Schmid J, Forstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int. J Geriatr. Psychiatry23, 754–759 (2008).
   PubMed Web of Science ®Google Scholar
• Boxer AL, Lipton AM, Womack K et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Discord.23, 211–217 (2009).
   PubMed Web of Science ®Google Scholar
• Collins SC, Sigtermans MJ, Dahan A, Zuurmond WW, Perez RS. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med.11, 1726–1742 (2010).
   PubMed Web of Science ®Google Scholar
• Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry32, 1362–1374 (2008).
   PubMedGoogle Scholar
• Zarate CA, Singh JB, Quiroz JA et al. A double-blind placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry163(1), 153–155 (2006).
   PubMed Web of Science ®Google Scholar
• Rao VL, Dogan A, Todd KG, Bowen KK, Dempsey RJ. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res.911(1), 96–100 (2001).
   PubMed Web of Science ®Google Scholar
• Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smit DH. A lack of amyloid β plaques despite persistent accumulation of amyloid β in axons of long-term survivors of traumatic brain injury. Brain Pathol.19(2), 214–233 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YW, Shin J, An Y. Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study. Ann. Nucl. Med.24, 363–369 (2010).
   PubMedGoogle Scholar
• Bassil N, Thaipissuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease. Expert Opin. Pharmacotherap.11, 1765–1771 (2010).
   PubMed Web of Science ®Google Scholar